Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications CNS cancer; Glioma; Li-Fraumeni syndrome; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Therapeutic Use
- Acronyms MATCH
- 26 Sep 2023 Planned End Date changed from 8 May 2024 to 22 Sep 2024.
- 06 Jun 2023 Results assessing safety and efficacy of Palbociclib in solid tumor patients presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 May 2023 Planned End Date changed from 30 Jun 2024 to 8 May 2024.